Compare Stocks: SGMT, NAMS, CLDX, and BEAM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.37 -6.0%	$26.99	$20.23 ▼ $38.26	$2.68B	2.22	1.82 million shs	1.90 million shs
CLDX Celldex Therapeutics	$31.12 -7.1%	$38.88	$22.10 ▼ $45.14	$2.63B	0.84	1.34 million shs	4.24 million shs
NAMS NewAmsterdam Pharma	$22.68 -2.7%	$26.60	$21.02 ▼ $42.21	$2.79B	0.09	1.61 million shs	2.27 million shs
SGMT Sagimet Biosciences	$10.42 -6.0%	$9.52	$4.50 ▼ $11.45	$689.34M	3.45	911,334 shs	1.12 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-6.02%	+5.50%	-13.98%	-28.18%	+2.70%
CLDX Celldex Therapeutics	-7.13%	-19.61%	-23.29%	-8.71%	+28.44%
NAMS NewAmsterdam Pharma	-2.74%	+7.08%	-15.53%	-28.52%	-14.96%
SGMT Sagimet Biosciences	-6.04%	-0.38%	+2.06%	+51.90%	+54.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.37 -6.0%	$26.99	$20.23 ▼ $38.26	$2.68B	2.22	1.82 million shs	1.90 million shs
CLDX Celldex Therapeutics	$31.12 -7.1%	$38.88	$22.10 ▼ $45.14	$2.63B	0.84	1.34 million shs	4.24 million shs
NAMS NewAmsterdam Pharma	$22.68 -2.7%	$26.60	$21.02 ▼ $42.21	$2.79B	0.09	1.61 million shs	2.27 million shs
SGMT Sagimet Biosciences	$10.42 -6.0%	$9.52	$4.50 ▼ $11.45	$689.34M	3.45	911,334 shs	1.12 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-6.02%	+5.50%	-13.98%	-28.18%	+2.70%
CLDX Celldex Therapeutics	-7.13%	-19.61%	-23.29%	-8.71%	+28.44%
NAMS NewAmsterdam Pharma	-2.74%	+7.08%	-15.53%	-28.52%	-14.96%
SGMT Sagimet Biosciences	-6.04%	-0.38%	+2.06%	+51.90%	+54.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	101.07% Upside
CLDX Celldex Therapeutics	2.86	Moderate Buy	$61.92	98.98% Upside
NAMS NewAmsterdam Pharma	2.85	Moderate Buy	$49.73	119.26% Upside
SGMT Sagimet Biosciences	2.73	Moderate Buy	$27.96	168.32% Upside

Current Analyst Ratings Breakdown

Latest SGMT, NAMS, CLDX, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	SGMT Sagimet Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
9/23/2026	CLDX Celldex Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$70.00 ➝ $88.00
9/23/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$50.00 ➝ $57.00
9/22/2026	CLDX Celldex Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$68.00
9/22/2026	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $64.00
9/22/2026	CLDX Celldex Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$61.00 ➝ $72.00
9/10/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$46.00 ➝ $50.00
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71
9/9/2026	SGMT Sagimet Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$8.00 ➝ $18.00
9/9/2026	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$156.04M	16.13	N/A	N/A	$12.20 per share	2.00
CLDX Celldex Therapeutics	$158K	15,467.43	N/A	N/A	$7.93 per share	3.92
NAMS NewAmsterdam Pharma	$22.50M	120.50	N/A	N/A	$5.97 per share	3.80
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	$3.42 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)

Latest SGMT, NAMS, CLDX, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.69%	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
CLDX Celldex Therapeutics	N/A	11.82	11.82
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
SGMT Sagimet Biosciences	N/A	45.03	45.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CLDX Celldex Therapeutics	N/A
NAMS NewAmsterdam Pharma	89.89%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
CLDX Celldex Therapeutics	5.20%
NAMS NewAmsterdam Pharma	12.74%
SGMT Sagimet Biosciences	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
CLDX Celldex Therapeutics	198	78.53 million	74.45 million	Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
SGMT Sagimet Biosciences	16	62.16 million	55.01 million	Optionable

SGMT, NAMS, CLDX, and BEAM Headlines

Recent News About These Companies

Cours Sagimet Biosciences Inc.

September 23 at 2:57 PM | zonebourse.comZ

Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 4.1% - Time to Buy?

September 10, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Upgraded at Cantor Fitzgerald

September 10, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $1.55 Million in Sagimet Biosciences Inc. $SGMT

September 10, 2026 | marketbeat.com

Cantor Fitzgerald initiates coverage of Sagimet Biosciences at overweight

September 9, 2026 | msn.com

Barclays upgrades Sagimet Biosciences to overweight from equal-weight

September 9, 2026 | msn.com

Sagimet Biosciences (NASDAQ:SGMT) Hits New 52-Week High - Here's Why

September 9, 2026 | marketbeat.com

Seven Fleet Capital Management LP Buys Shares of 403,545 Sagimet Biosciences Inc. $SGMT

September 5, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Sets New 1-Year High - Should You Buy?

September 3, 2026 | marketbeat.com

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts

August 31, 2026 | marketbeat.com

Sagimet Biosciences' (SGMT) Buy Rating Reiterated at HC Wainwright

August 25, 2026 | marketbeat.com

Sagimet Biosciences Announces AURORA Phase 3 Acne Trial on Track to Begin Enrollment in Q4 2026

August 25, 2026 | quiverquant.comQ

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

August 25, 2026 | globenewswire.com

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026 | markets.businessinsider.com

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026 | globenewswire.com

FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study

August 14, 2026 | kalkinemedia.comK

Sagimet Biosciences Receives US FDA Clearance for Phase 3 Acne Trial

August 13, 2026 | finance.yahoo.com

Sagimet higher on FDA clearance of late-stage acne trial

August 13, 2026 | msn.com

Sagimet Biosciences Inc.: Sagimet Biosciences Receives FDA "Study May Proceed" Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

August 13, 2026 | finanznachrichten.de

Analysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), BridgeBio Pharma (BBIO)

August 13, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT, NAMS, CLDX, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$24.37 -1.56 (-6.02%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$24.20 -0.17 (-0.69%)

As of 07:00 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Celldex Therapeutics NASDAQ:CLDX

$31.12 -2.39 (-7.13%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$30.81 -0.31 (-1.00%)

As of 06:56 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

NewAmsterdam Pharma NASDAQ:NAMS

$22.68 -0.64 (-2.74%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$22.70 +0.02 (+0.07%)

As of 06:51 AM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Sagimet Biosciences NASDAQ:SGMT

$10.42 -0.67 (-6.04%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$10.14 -0.28 (-2.68%)

As of 06:45 AM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGMT, NAMS, CLDX, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGMT, NAMS, CLDX, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGMT, NAMS, CLDX, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT, NAMS, CLDX, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

NewAmsterdam Pharma NASDAQ:NAMS

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGMT, NAMS, CLDX, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGMT, NAMS, CLDX, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGMT, NAMS, CLDX, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT, NAMS, CLDX, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

NewAmsterdam Pharma NASDAQ:NAMS

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools